OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.79
+0.90%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.80
From 52W high−68.25%
Volume4.45M
Market cap$266.98M
P/E (TTM)—
P/S (TTM)58.3x
Div yield—
Key dataOct 19, 2026
Open
$0.80
From 52W high
−68.25%
Volume
4.45M
Market cap
$266.98M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
P/E (TTM)
—
RSI (14)
27.8
MomentumView details →
1D Return
+0.90%
YTD Return
−40.12%
SummaryUpdated Jun 1, 2026
Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Malvern, Pennsylvania. The company went public in December 2014 and has evolved from its initial focus on COVID-19 vaccines to become a specialized developer of gene therapies for inherited retinal diseases. Ocugen is currently advancing multiple clinical programs targeting various forms of blindness, with three potential biologics license applications planned for filing within the next three years.
Similar companies
Latest newsMore news →
Ocugen agreed to manufacture and supply the licensed OCU400 product to Roots Pharmaceutical Company WLL.5d agoOcugen, Inc. announced a licensing agreement granting Roots Pharmaceutical and its strategic partner Al-Dhow International Holding exclusive rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa.6d agoThe Third Circuit abrogated the Oran-Burlington rule and vacated the dismissal of a securities fraud class action against Ocugen, Inc. and its chief executive, returning the case to the district court.18d ago